Anvicure Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 25-12-2024
- Paid Up Capital ₹ 0.60 M
as on 25-12-2024
- Company Age 5 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.00 M
as on 25-12-2024
- Revenue -24.38%
(FY 2023)
- Profit -42.22%
(FY 2023)
- Ebitda 10.29%
(FY 2023)
- Net Worth 17.35%
(FY 2023)
- Total Assets -26.20%
(FY 2023)
About Anvicure Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.60 M.
The company currently has active open charges totaling ₹5.00 M.
Rahul and Kavita Devi serve as directors at the Company.
- CIN/LLPIN
U74999HP2019PTC007326
- Company No.
007326
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Jan 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Himachal Pradesh
Industry
Company Details
- Location
Sirmaur, Himachal Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Anvicure Drugs Private Limited offer?
Anvicure Drugs Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Vitamin & Multivitamin Injections, Healthcare Products & Aids, Health Drinks, Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Pain Relief Drugs & Pharmaceuticals, Osteoporosis Medications, Digestive System Drugs & Medicines, Pre & Probiotic Capsule.
Who are the key members and board of directors at Anvicure Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rahul  | Director | 31-Jan-2019 | Current |
| Kavita Devi | Additional Director | 23-Aug-2024 | Current |
Financial Performance of Anvicure Drugs.
Anvicure Drugs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 24.38% decrease. The company also saw a substantial fall in profitability, with a 42.22% decrease in profit. The company's net worth Soared by an impressive increase of 17.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Anvicure Drugs?
In 2023, Anvicure Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹5.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Nov 2020 | Others | ₹5.00 M | Open |
How Many Employees Work at Anvicure Drugs?
Unlock and access historical data on people associated with Anvicure Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Anvicure Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Anvicure Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
